John R. Mackey

40.9k total citations · 11 hit papers
335 papers, 24.6k citations indexed

About

John R. Mackey is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, John R. Mackey has authored 335 papers receiving a total of 24.6k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Oncology, 89 papers in Molecular Biology and 68 papers in Cancer Research. Recurrent topics in John R. Mackey's work include Cancer Treatment and Pharmacology (59 papers), Cancer survivorship and care (55 papers) and HER2/EGFR in Cancer Research (44 papers). John R. Mackey is often cited by papers focused on Cancer Treatment and Pharmacology (59 papers), Cancer survivorship and care (55 papers) and HER2/EGFR in Cancer Research (44 papers). John R. Mackey collaborates with scholars based in Canada, United States and France. John R. Mackey's co-authors include Kerry S. Courneya, Lee W. Jones, Carol E. Cass, Charles Dumontet, Mark J. Haykowsky, Adrian Fairey, Karen A. Gelmon, Evangelos D. Michelakis, Christine M. Friedenreich and Donald C. McKenzie and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Nature Communications.

In The Last Decade

John R. Mackey

327 papers receiving 23.9k citations

Hit Papers

Effects of Aerobic and Resistance Exercise in Breast Canc... 2002 2026 2010 2018 2007 2009 2002 2003 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial
    2007 866 citations Kerry S. Courneya, John R. Mackey et al. Journal of Clinical Oncology profile →
  2. Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
    2009 856 citations Carla M. Prado, Katia Tonkin et al. Clinical Cancer Research profile →
  3. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    2002 676 citations Anthony Howell, John R. Mackey et al. profile →
  4. Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
    2003 657 citations Anthony Howell, John R. Mackey et al. profile →
  5. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
    2009 596 citations John R. Mackey et al. Journal of Clinical Oncology profile →
  6. Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes
    2003 589 citations Kerry S. Courneya, John R. Mackey et al. Journal of Clinical Oncology profile →
  7. Metabolic Modulation of Glioblastoma with Dichloroacetate
    2010 575 citations John R. Mackey, Bassam Abdulkarim et al. profile →
  8. Gastric Adenocarcinoma
    2005 547 citations Carol E. Cass, John R. Mackey et al. profile →
  9. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
    2008 546 citations John R. Mackey et al. profile →
  10. Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum
    2012 322 citations Lee W. Jones, Kerry S. Courneya et al. Journal of Clinical Oncology profile →
  11. Incident Cardiovascular Disease Among Adults With Cancer
    2022 101 citations D. Ian Paterson, John R. Mackey et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John R. Mackey Canada 84 14.8k 5.9k 4.6k 4.0k 3.1k 335 24.6k
Dawn L. Hershman United States 82 12.7k 0.9× 2.3k 0.4× 3.9k 0.8× 3.5k 0.9× 1.9k 0.6× 717 27.2k
Karen A. Gelmon Canada 73 15.9k 1.1× 5.6k 1.0× 6.6k 1.4× 7.0k 1.8× 1.4k 0.4× 393 23.8k
Hyman B. Muss United States 84 17.2k 1.2× 2.9k 0.5× 5.7k 1.2× 9.4k 2.4× 1.4k 0.4× 556 29.7k
Howard L. McLeod United States 81 10.1k 0.7× 9.6k 1.6× 2.6k 0.6× 2.9k 0.7× 2.6k 0.8× 481 26.6k
Clifford A. Hudis United States 93 23.6k 1.6× 8.2k 1.4× 6.9k 1.5× 14.1k 3.5× 1.2k 0.4× 509 39.7k
Kevin Stein United States 43 8.4k 0.6× 3.2k 0.5× 3.3k 0.7× 1.9k 0.5× 2.7k 0.9× 112 16.3k
Lynn A. G. Ries United States 56 13.0k 0.9× 4.1k 0.7× 6.6k 1.4× 3.6k 0.9× 2.6k 0.8× 81 26.7k
Carol DeSantis United States 32 13.0k 0.9× 7.8k 1.3× 5.1k 1.1× 6.4k 1.6× 1.7k 0.5× 55 28.2k
Michael Gnant Austria 71 13.1k 0.9× 7.8k 1.3× 5.6k 1.2× 10.0k 2.5× 922 0.3× 555 37.9k
Kathleen I. Pritchard Canada 72 15.6k 1.1× 6.1k 1.0× 5.4k 1.2× 9.9k 2.5× 809 0.3× 369 25.4k

Countries citing papers authored by John R. Mackey

Since Specialization
Citations

This map shows the geographic impact of John R. Mackey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Mackey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Mackey more than expected).

Fields of papers citing papers by John R. Mackey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Mackey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Mackey. The network helps show where John R. Mackey may publish in the future.

Co-authorship network of co-authors of John R. Mackey

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Mackey. A scholar is included among the top collaborators of John R. Mackey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Mackey. John R. Mackey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beauchamp, Erwan, Christopher R. Cromwell, Morris A. Kostiuk, et al.. (2024). Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition. Journal of Translational Medicine. 22(1). 431–431. 7 indexed citations
2.
Dinakaran, Deepak, et al.. (2023). Photon Absorption Remote Sensing Imaging of Breast Needle Core Biopsies Is Diagnostically Equivalent to Gold Standard H&E Histologic Assessment. Current Oncology. 30(11). 9760–9771. 3 indexed citations
3.
Hugh, Judith, Gilbert Bigras, Xiuying Hu, et al.. (2021). DREAM, a possible answer to the estrogen paradox of the Women's Health Initiative Trial. Heliyon. 8(1). e08666–e08666. 2 indexed citations
4.
Lewis, Cody W., Amirali B. Bukhari, Wonshik Choi, et al.. (2019). Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition. Cancer Research. 79(23). 5971–5985. 47 indexed citations
5.
Press, Michael F., José A. Seoane, Christina Curtis, et al.. (2018). Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncology. 5(3). 366–366. 25 indexed citations
6.
Pituskin, Edith, John R. Mackey, Sheri L. Koshman, et al.. (2017). Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology. 35(8). 870–877. 253 indexed citations
7.
Spera, Gonzalo, Rodrigo Fresco, Hoki Fung, et al.. (2017). Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Annals of Oncology. 28(8). 1836–1841. 55 indexed citations
8.
Sawyer, Michael B., Edith Pituskin, Sambasivarao Damaraju, et al.. (2015). A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clinical Breast Cancer. 16(2). 139–144.e3. 17 indexed citations
9.
Stern, Howard M., Humphrey Gardner, Tomasz Burzykowski, et al.. (2015). PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research. 21(9). 2065–2074. 57 indexed citations
10.
Tang, Yanan, John R. Mackey, Raymond Lai, et al.. (2013). Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification. Journal of Proteomics. 91. 200–209. 7 indexed citations
11.
McNeely, Margaret L., Kristin L. Campbell, Maria B. Ospina, et al.. (2010). Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database of Systematic Reviews. 2010(6). CD005211–CD005211. 238 indexed citations
12.
Dumontet, Charles, Maryla Krajewska, Isabelle Treilleux, et al.. (2010). BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. Clinical Cancer Research. 16(15). 3988–3997. 33 indexed citations
13.
Lesniak, David, Yaoxian Xu, Jean Deschênes, et al.. (2009). β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer. Cancer Research. 69(22). 8620–8628. 71 indexed citations
14.
Haykowsky, Mark J., John R. Mackey, Richard B. Thompson, Lee W. Jones, & D. Ian Paterson. (2009). Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training. Clinical Cancer Research. 15(15). 4963–4967. 96 indexed citations
15.
Hugh, Judith, John Hanson, Maggie C.U. Cheang, et al.. (2009). Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. Journal of Clinical Oncology. 27(8). 1168–1176. 407 indexed citations
16.
Burzykowski, Tomasz, Marc Buyse, Martine Piccart, et al.. (2008). Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1987–1992. 268 indexed citations
17.
Eastell, Richard, Judith E. Adams, Robert E. Coleman, et al.. (2008). Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology. 26(7). 1051–1057. 306 indexed citations
18.
Vallance, Jeffrey K., Kerry S. Courneya, Ronald C. Plotnikoff, & John R. Mackey. (2008). Analyzing Theoretical Mechanisms of Physical Activity Behavior Change in Breast Cancer Survivors: Results from the Activity Promotion (ACTION) Trial. Annals of Behavioral Medicine. 35(2). 150–158. 91 indexed citations
19.
Jones, Lee W., Kerry S. Courneya, Adrian Fairey, & John R. Mackey. (2005). Does the Theory of Planned Behavior Mediate the Effects of an Oncologist's Recommendation to Exercise in Newly Diagnosed Breast Cancer Survivors? Results From a Randomized Controlled Trial.. Health Psychology. 24(2). 189–197. 75 indexed citations
20.
Dabbagh, Laith, Robert Coupland, Carol E. Cass, & John R. Mackey. (2003). Correspondence Re: J. R. Mackey et al., ImmunohistochemicalVariation of Human Equilibrative Nucleoside Transporter 1 Protein inPrimary Breast Cancers. Clin. Cancer Res., 8: 110ndash;116, 2002.. Clinical Cancer Research. 9(8). 3213–3214. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dawn L. Hershman Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Hyman B. Muss Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Clifford A. Hudis Breakdown of academic impact, for papers by Kevin Stein Breakdown of academic impact, for papers by Lynn A. G. Ries Breakdown of academic impact, for papers by Carol DeSantis Breakdown of academic impact, for papers by Michael Gnant Breakdown of academic impact, for papers by Kathleen I. Pritchard
Rankless by CCL
2026